2024
Trends and predictors of Quality of Life in lung cancer survivors
Bade B, Zhao J, Li F, Tanoue L, Lazowski H, Alfano C, Silvestri G, Irwin M. Trends and predictors of Quality of Life in lung cancer survivors. Lung Cancer 2024, 191: 107793. PMID: 38640687, DOI: 10.1016/j.lungcan.2024.107793.Peer-Reviewed Original ResearchConceptsFunctional Assessment of Cancer Therapy - LungNon-small cell lung cancerHR-QOL scoresLung cancer survivorsHR-QOLAdvanced stage non-small cell lung cancerEarly-stage non-small cell lung cancerStage non-small cell lung cancerQuality of lifeCancer survivorsPhysical activityCell lung cancerEarly-stage diseasePredictors of quality of lifeHealth-related quality of lifeFollow-upHealth-related qualityHealthy weight maintenancePerformance statusAdvanced-stage non-small cell lung cancerLung cancerClinical significanceAssociated with older ageDiagnosed NSCLCTreatment-related side effects
2020
A 62-Year-Old Woman With Lung Cancer, Ulcerating Rash, and Rapidly Progressive Hypoxemia
Kunitomo Y, Young G, Datta R, Korn LL, Tanoue L, Gautam S. A 62-Year-Old Woman With Lung Cancer, Ulcerating Rash, and Rapidly Progressive Hypoxemia. CHEST Journal 2020, 158: e191-e196. PMID: 33036118, PMCID: PMC7533682, DOI: 10.1016/j.chest.2020.06.020.Peer-Reviewed Case Reports and Technical Notes
2018
Improved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static 18F-FDG PET as a function of injected dose
Ye Q, Wu J, Lu Y, Naganawa M, Gallezot JD, Ma T, Liu Y, Tanoue L, Detterbeck F, Blasberg J, Chen MK, Casey M, Carson RE, Liu C. Improved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static 18F-FDG PET as a function of injected dose. Physics In Medicine And Biology 2018, 63: 175015. PMID: 30095083, PMCID: PMC6158045, DOI: 10.1088/1361-6560/aad97f.Peer-Reviewed Original ResearchConceptsPopulation-based input functionStandardized uptake valueImage-derived input functionLung nodulesClinical trialsTime-activity curvesLow-dose computed tomography (LDCT) screeningLung cancer mortality ratesIndeterminate lung nodulesComputed Tomography ScreeningF-FDG PETCancer mortality ratesStatic PET acquisitionVirtual clinical trialsScan durationTomography screeningFDG injectionPET scansMortality rateUptake valueAccurate diagnosisMalignant lung nodulesROC analysisPatient dataMalignant nodulesIncorporating Coexisting Chronic Illness into Decisions about Patient Selection for Lung Cancer Screening. An Official American Thoracic Society Research Statement
Rivera MP, Tanner NT, Silvestri GA, Detterbeck FC, Tammemägi MC, Young RP, Slatore CG, Caverly TJ, Boyd CM, Braithwaite D, Fathi JT, Gould MK, Iaccarino JM, Malkoski SP, Mazzone PJ, Tanoue LT, Schoenborn NL, Zulueta JJ, Wiener RS. Incorporating Coexisting Chronic Illness into Decisions about Patient Selection for Lung Cancer Screening. An Official American Thoracic Society Research Statement. American Journal Of Respiratory And Critical Care Medicine 2018, 198: e3-e13. PMID: 30004250, DOI: 10.1164/rccm.201805-0986st.Peer-Reviewed Original ResearchConceptsLung cancer screeningRisk of deathPatient selectionChronic illnessCancer screeningLung cancerOfficial American Thoracic Society Research StatementHarms of LCSImplementation of LCSScreen-detected lung cancersChronic obstructive pulmonary diseaseRisk of comorbiditiesObstructive pulmonary diseaseEffect of comorbidityLung cancer deathsTreatment-related harmsLung cancer riskBalance of benefitsPulmonary diseaseCancer deathBaseline riskCancer riskComorbiditiesHealthy individualsInternational clinicians
2015
Effects of One-Hour Training Course and Spirometry on the Ability of Physicians to Diagnose and Treat Chronic Obstructive Pulmonary Disease
Cai S, Qin L, Tanoue L, Hu A, Jia X, Luo H, Chen Y, Chen P, Peng H. Effects of One-Hour Training Course and Spirometry on the Ability of Physicians to Diagnose and Treat Chronic Obstructive Pulmonary Disease. PLOS ONE 2015, 10: e0117348. PMID: 25706774, PMCID: PMC4338104, DOI: 10.1371/journal.pone.0117348.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseAbility of physiciansSpirometric dataPulmonary diseasePresence of COPDPrevalence of COPDSeverity of COPDPatient subjectsPersons 40 yearsMean correct scoreTraining sessionsCOPD guidelinesCOPD severityPhysician visitsSpirometry resultsPhysician subjectsSecondary hospitalsSpirometric resultsPhysicians' knowledgeSpirometryPhysician responsesPhysiciansPatientsHospitalLung Cancer Screening
Tanoue LT, Tanner NT, Gould MK, Silvestri GA. Lung Cancer Screening. American Journal Of Respiratory And Critical Care Medicine 2015, 191: 19-33. PMID: 25369325, DOI: 10.1164/rccm.201410-1777ci.Peer-Reviewed Original ResearchConceptsLow-dose computed tomographyLung cancerUnited States Preventive Services Task ForcePack-year smoking historyNational Lung Screening TrialLung cancer screeningUnnecessary invasive testingFalse-positive findingsAspects of screeningLDCT screeningSmoking historyCancer screeningMortality burdenInvasive testingHigh riskScreening TrialComputed tomographyRisk of harmAge 55Positive findingsCancerEffective screeningPossible harmScreeningTask Force
2011
Molecular classification of nonsmall cell lung cancer using a 4‐protein quantitative assay
Anagnostou VK, Dimou AT, Botsis T, Killiam EJ, Gustavson MD, Homer RJ, Boffa D, Zolota V, Dougenis D, Tanoue L, Gettinger SN, Detterbeck FC, Syrigos KN, Bepler G, Rimm DL. Molecular classification of nonsmall cell lung cancer using a 4‐protein quantitative assay. Cancer 2011, 118: 1607-1618. PMID: 22009766, DOI: 10.1002/cncr.26450.Peer-Reviewed Original Research
2010
High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 2010, 10: 186. PMID: 20459695, PMCID: PMC2875218, DOI: 10.1186/1471-2407-10-186.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBiomarkers, TumorCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell DifferentiationCohort StudiesConnecticutFemaleGreeceHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm StagingPredictive Value of TestsProportional Hazards ModelsProto-Oncogene Proteins c-bcl-2Reproducibility of ResultsRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUp-RegulationConceptsNon-small cell lung cancer patientsCell lung cancer patientsNon-squamous tumorsLung cancer patientsBcl-2 expressionNSCLC patientsCancer patientsBcl-2Favorable outcomeIndependent cohortSmall cell lung cancer patientsIndependent lower riskNon-squamous histologySubgroup of patientsHigh expressersSquamous cell carcinomaHigh Bcl-2 expressionBcl-2 protein levelsSquamous histologyMedian survivalPrognostic factorsValidation cohortCell carcinomaPathological characteristicsPrognostic stratification
2009
High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma
Anagnostou VK, Bepler G, Syrigos KN, Tanoue L, Gettinger S, Homer RJ, Boffa D, Detterbeck F, Rimm DL. High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma. Clinical Cancer Research 2009, 15: 4157-4164. PMID: 19509151, DOI: 10.1158/1078-0432.ccr-09-0099.Peer-Reviewed Original ResearchConceptsLung cancer patientsMTOR expressionCancer patientsMammalian targetEarly-stage lung adenocarcinomaHigh mTOR expressionIndependent lower riskMedian overall survivalStage IA patientsProtein expressionSubgroup of patientsLung adenocarcinoma patientsStage lung adenocarcinomaMTOR protein expressionRole of mTOROverall survivalPathologic characteristicsPatient survivalValidation cohortAdenocarcinoma groupAdenocarcinoma patientsPrognostic stratificationLung cancerTraining cohortFavorable outcome
2007
Massive Intravascular Hemolysis and a Rapidly Fatal Outcome
Kapoor JR, Monteiro B, Tanoue L, Siegel MD. Massive Intravascular Hemolysis and a Rapidly Fatal Outcome. CHEST Journal 2007, 132: 2016-2019. PMID: 18079238, DOI: 10.1378/chest.07-0853.Peer-Reviewed Original Research
2006
High Rate of Negative Results of Tuberculin and QuantiFERON Tests Among Individuals With a History of Positive Skin Test Results
Friedman LN, Nash ER, Bryant J, Henry S, Shi J, D'Amato J, Khaled GH, Russi MB, O'Connor PG, Edberg SC, Pisani MA, Cain HC, Tanoue L, Weissman DN. High Rate of Negative Results of Tuberculin and QuantiFERON Tests Among Individuals With a History of Positive Skin Test Results. Infection Control And Hospital Epidemiology 2006, 27: 436-441. PMID: 16671022, DOI: 10.1086/503690.Peer-Reviewed Original ResearchConceptsQuantiFERON-TB testTuberculin skin testPrevious tuberculin skin testTST statusInitial tuberculin skin testPositive tuberculin skin testSecond tuberculin skin testPositive skin test resultsExperienced healthcare workersNegative TST resultsTST-negative groupSkin test resultsTST protocolWhole blood assaysNegative resultsPositive resultsTuberculosis exposureImmunocompetent subjectsQuantiFERON testSkin testTST resultsMedical recordsInduration diameterHealthcare workersHigh risk
2005
Case Study Review
Noble PW, Tanoue L, Homer R. Case Study Review. CHEST Journal 2005, 128: 540s-546s. PMID: 16304245, DOI: 10.1378/chest.128.5_suppl_1.540s.Peer-Reviewed Original Research
1999
Assessment of Cardiac and Pulmonary Function in Adult Patients with Hodgkin's Disease Treated with ABVD or MOPP/ABVD Plus Adjuvant Low-Dose Mediastinal Irradiation
Salloum E, Tanoue L, Wackers F, Zelterman D, Hu G, Cooper D. Assessment of Cardiac and Pulmonary Function in Adult Patients with Hodgkin's Disease Treated with ABVD or MOPP/ABVD Plus Adjuvant Low-Dose Mediastinal Irradiation. Cancer Investigation 1999, 17: 171-180. PMID: 10099655, DOI: 10.3109/07357909909021418.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinCombined Modality TherapyDacarbazineDose-Response Relationship, RadiationDoxorubicinEvaluation Studies as TopicFemaleFollow-Up StudiesHeartHodgkin DiseaseHumansLungMaleMechlorethamineMiddle AgedPhysical ExertionPrednisoneProcarbazineRadiotherapy, AdjuvantRemission InductionRespiratory Function TestsVinblastineVincristineConceptsLeft ventricular ejection fractionMOPP/ABVDHodgkin's diseaseAdult patientsPulmonary functionInvolved-field radiation therapyFEV1/FVC ratioIU/m2Pulmonary function testsVentricular ejection fractionVital capacity valuesTotal lung capacityMediastinal irradiationPulmonary symptomsDiastolic functionModality therapyEjection fractionCardiopulmonary functionFunction testsFVC ratioStudy abnormalitiesCigarette smokersCardiac toxicityLung capacitySuch therapy
1998
PULMONARY MANIFESTATIONS OF RHEUMATOID ARTHRITIS
Tanoue L. PULMONARY MANIFESTATIONS OF RHEUMATOID ARTHRITIS. Clinics In Chest Medicine 1998, 19: 667-685. PMID: 9917959, DOI: 10.1016/s0272-5231(05)70109-x.Peer-Reviewed Original ResearchConceptsRheumatoid arthritisClassic connective tissue diseasesTherapy-related toxicityConnective tissue diseasePulmonary manifestationsPulmonary evaluationRespiratory complaintsTissue diseasePulmonary vasculatureRadiographic findingsPhysiologic abnormalitiesLung parenchymaArthritisPatientsManifestationsAirwayPleuraChestAbnormalitiesDiseaseComplaintsParenchymaVasculature
1992
Lung transplantation
Tanoue L. Lung transplantation. Lung 1992, 170: 187-200. PMID: 1522739, DOI: 10.1007/bf00174116.Peer-Reviewed Original ResearchConceptsLung transplantationEnd-stage lung diseaseHuman lung transplantationSolid organ transplantationProper patient selectionLong-term managementPosttransplantation complicationsPatient selectionLung diseaseClinical indicationsOrgan transplantationTransplantationMerit particular attentionComplicationsPatientsInfectionDisease